178 related articles for article (PubMed ID: 27741010)
61. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma.
Konski AA; Cheng JD; Goldberg M; Li T; Maurer A; Yu JQ; Haluszka O; Scott W; Meropol NJ; Cohen SJ; Freedman G; Weiner LM
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):358-63. PubMed ID: 17532577
[TBL] [Abstract][Full Text] [Related]
62. Comparison of (18)F-FDG PET/CT methods of analysis for predicting response to neoadjuvant chemoradiation therapy in patients with locally advanced low rectal cancer.
Altini C; Niccoli Asabella A; De Luca R; Fanelli M; Caliandro C; Quartuccio N; Rubini D; Cistaro A; Montemurro S; Rubini G
Abdom Imaging; 2015 Jun; 40(5):1190-202. PubMed ID: 25348731
[TBL] [Abstract][Full Text] [Related]
63. Utility of restaging endoscopic ultrasound after neoadjuvant therapy for esophageal cancer.
Griffin JM; Reed CE; Denlinger CE
Ann Thorac Surg; 2012 Jun; 93(6):1855-9; discussion 1860. PubMed ID: 22516835
[TBL] [Abstract][Full Text] [Related]
64. Evaluation of progression prior to surgery after neoadjuvant chemoradiotherapy with computed tomography in esophageal cancer patients.
Hulshoff JB; Smit JK; van der Jagt EJ; Plukker JT
Am J Surg; 2014 Jul; 208(1):73-9. PubMed ID: 24476969
[TBL] [Abstract][Full Text] [Related]
65. Comparative study between endoscopic ultrasonography and positron emission tomography-computed tomography in staging patients with esophageal squamous cell carcinoma.
Yen TJ; Chung CS; Wu YW; Yen RF; Cheng MF; Lee JM; Hsu CH; Chang YL; Wang HP
Dis Esophagus; 2012 Jan; 25(1):40-7. PubMed ID: 21595776
[TBL] [Abstract][Full Text] [Related]
66. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging.
Erasmus JJ; Munden RF; Truong MT; Ho JJ; Hofstetter WL; Macapinlac HA; Correa AM; Wu TT; Bruzzi JF; Marom EM; Sabloff BS; Ajani JA; Komaki R; Liao Z; Lee JH; Fukami N; Bresalier R; Swisher SG
J Thorac Oncol; 2006 Jun; 1(5):478-86. PubMed ID: 17409902
[TBL] [Abstract][Full Text] [Related]
67. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
Malik V; Lucey JA; Duffy GJ; Wilson L; McNamara L; Keogan M; Gillham C; Reynolds JV
J Nucl Med; 2010 Dec; 51(12):1863-9. PubMed ID: 21078796
[TBL] [Abstract][Full Text] [Related]
68. DW-MRI and DCE-MRI are of complementary value in predicting pathologic response to neoadjuvant chemoradiotherapy for esophageal cancer.
Heethuis SE; Goense L; van Rossum PSN; Borggreve AS; Mook S; Voncken FEM; Bartels-Rutten A; Aleman BMP; van Hillegersberg R; Ruurda JP; Meijer GJ; Lagendijk JJW; van Lier ALHMW
Acta Oncol; 2018 Sep; 57(9):1201-1208. PubMed ID: 29781342
[TBL] [Abstract][Full Text] [Related]
69. 18F-FDG PET-CT after Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients to Optimize Surgical Decision Making.
Anderegg MC; de Groof EJ; Gisbertz SS; Bennink RJ; Lagarde SM; Klinkenbijl JH; Dijkgraaf MG; Bergman JJ; Hulshof MC; van Laarhoven HW; van Berge Henegouwen MI
PLoS One; 2015; 10(11):e0133690. PubMed ID: 26529313
[TBL] [Abstract][Full Text] [Related]
70. Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer?
Liu SL; Xi M; Yang H; Yang YD; Wu YJ; Zhao L; Zhang P; Luo LL; Liu MZ
Ann Surg Oncol; 2016 Jan; 23(1):273-81. PubMed ID: 26215200
[TBL] [Abstract][Full Text] [Related]
71. Measuring tumor hypoxia with ¹⁸F-FETNIM PET in esophageal squamous cell carcinoma: a pilot clinical study.
Yue J; Yang Y; Cabrera AR; Sun X; Zhao S; Xie P; Zheng J; Ma L; Fu Z; Yu J
Dis Esophagus; 2012 Jan; 25(1):54-61. PubMed ID: 21595781
[TBL] [Abstract][Full Text] [Related]
72. Clinical response assessment on DW-MRI compared with FDG-PET/CT after neoadjuvant chemoradiotherapy in patients with oesophageal cancer.
Vollenbrock SE; Voncken FEM; Lambregts DMJ; Maas M; Donswijk ML; Vegt E; Ter Beek LC; van Dieren JM; van Sandick JW; Aleman BMP; Beets-Tan RGH; Bartels-Rutten A
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):176-185. PubMed ID: 32572560
[TBL] [Abstract][Full Text] [Related]
73. Predictive value of endoscopic esophageal findings for residual esophageal cancer after neoadjuvant chemoradiotherapy.
van der Bogt RD; van der Wilk BJ; Nikkessen S; Krishnadath KK; Schoon EJ; Oostenbrug LE; Siersema PD; Vleggaar FP; Doukas M; van Lanschot JJB; Spaander MCW
Endoscopy; 2021 Nov; 53(11):1098-1104. PubMed ID: 33652496
[TBL] [Abstract][Full Text] [Related]
74. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
[TBL] [Abstract][Full Text] [Related]
75. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152
[TBL] [Abstract][Full Text] [Related]
76. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
[TBL] [Abstract][Full Text] [Related]
77. PET/CT predicts survival in patients undergoing primary surgery for esophageal cancer.
Lindner K; Palmes D; Senninger N; Hummel R
Langenbecks Arch Surg; 2015 Feb; 400(2):229-35. PubMed ID: 25572665
[TBL] [Abstract][Full Text] [Related]
78. Characterization of residual tumours at the primary site in patients with a near pathological complete response after neoadjuvant chemoradiotherapy for oesophageal cancer.
Chao YK; Chang Y; Yeh CJ; Chang HK; Tseng CK; Chuang WY
Br J Surg; 2016 Dec; 103(13):1874-1879. PubMed ID: 27620361
[TBL] [Abstract][Full Text] [Related]
79. Prognostic value of metabolic response measured by 18F-FDG-PET in oesophageal cancer patients treated with definitive chemoradiotherapy.
Onal C; Torun N; Guler OC; Yildirim BA
Nucl Med Commun; 2016 Dec; 37(12):1282-1289. PubMed ID: 27612030
[TBL] [Abstract][Full Text] [Related]
80. The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation.
Huh JW; Min JJ; Lee JH; Kim HR; Kim YJ
Am J Clin Oncol; 2012 Aug; 35(4):340-4. PubMed ID: 21422901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]